IPPRA / Grant Monitor

2026-07-07
← Board

INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)

RFA-OD-27-005 · National Institutes of Health

biomedical clinical public health education workforce social services Health

Closes
2028-06-15 · 709 d
Award ceiling
Award floor
Program funding
$3,000,000
Expected awards
4
Cost sharing
No
Posted
2026-05-13
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

NIH will fund milestone-driven phased R61/R33 clinical trial development projects to treat critical co-occurring health conditions in people with Down syndrome, with up to 2 years of preliminary/developmental work and up to 3 additional years for the trial phase.

Funds
applied research
University
direct
social behavioral
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Clinical trial required. · R61/R33 phased award with required measurable R61 milestones. · Total project period may not exceed 5 years. · Foreign organizations and foreign components are allowed.

Unit fits — one characterization, each unit's own rules

IPPRA 58 good peripheral portfolio topic: public_health; social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Physical Sciences & Engineering (demo) 55 good technical depth: minor; funds applied research
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this NOFO may not exceed five years. This NOFO provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This NOFO requires measurable R61 milestones.

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <DownSyndromeINCLUDE@mail.nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING